Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-12 · accession 0001104659-26-028656 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-16 | 2026-03-12 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +20.2K | 393.9K | +5% | $0 |
| D | 2026-03-16 | 2026-03-12 | APRE | Gilad Oren | Pres, CEO, Dir | A - Grant | $0.00 | +80.7K | 80.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-12 | A | A | 20,175 | $0.00 | 393,895 | D | — | — | (F1) These shares represent restricted stock units and shall vest and be settled in the Issuer's common stock in three (3) equal annual installments beginning on March 12, 2027, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |
| 2 | Derivative | Stock Options (Right to Buy) | 2026-03-12 | A | A | 80,700 | $0.00 | 80,700 | D | $0.77 · — to 2036-03-12 | 80,700 Common Stock | (F3) Twenty-five percent of these options vest on March 12, 2027, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. |